This study evaluated the success of sham-continuous positive airway pressure (CPAP) as a placebo in a 4-week clinical trial of adults with sleep apnea. Participants (n ¼ 23) were previously undiagnosed for obstructive sleep apnea, had no one in their household on sleep apnea therapy, and were willing to be randomly assigned to either active or sham-CPAP. Before final debriefing, participants were asked to ''guess'' their group assignment. When questioned, 10 of the 23 participants (44%) were incorrect in their guess of group assignment; 2 of these participants stated that their guess was ''random.'' The active CPAP group's average usage was significantly longer when compared to participants on the sham device (293 + 117 min/day vs. 188 + 110 min/day, p ¼ .046). The results suggest that participants remained blinded to group assignment and that sham-CPAP is an appropriate placebo control device. Participants' lower adherence to the sham device may be a potential problem that requires attention in the use of sham-CPAP as a placebo during clinical trials.
A randomized clinical trial, considered the most rigorous study approach to determine treatment efficacy, requires an appropriate control group. Investigators use blinding to treatment group assignment in clinical trials to prevent potential problems when either the investigator or participant becomes biased because of knowledge of the assigned intervention (Friedman, Furberg, & DeMets, 2010) . In order to successfully blind participants to treatment group assignment, researchers must use a comparable placebo treatment. In addition, they must pay attention to ethical issues at all stages of a clinical trial, especially one that involves the delay of treatment and the use of an elaborate placebo control device.
Continuous positive airway pressure (CPAP), considered the most effective treatment for obstructive sleep apnea (OSA), reduces or eliminates apneas and hypopneas during sleep, improves sleep architecture and continuity, and improves self-reported daytime functioning (Gay, Weaver, Loube, & Iber, 2006) . Early clinical trials that evaluated the efficacy of CPAP treatment were criticized because of the use of noncomparable control groups that utilized oral placebo tablets (Barnes et al., 2002; Barnes et al., 2004; Engleman et al., 1999; Engleman, Martin, Deary, & Douglas, 1997; Faccenda, Mackay, Boon, & Douglas, 2001) or conservative treatment (instruction not to sleep supine and use of nasal strips; Ballester et al., 1999; Monasterio et al., 2001; Redline et al., 1998) . Karlawish and Pack (2001) explained that these methods fail to evaluate the impact of positive pressure or the effect of the technological interface on CPAP efficacy. An additional problem with the use of oral placebo tablets was that the researchers could maintain blindness only if they told participants that the tablets may have efficacy, which presents an ethical dilemma because of the lack of veracity toward participants. Farré et al. (1999) first described the development of sham-CPAP in 1999. A refinement of this device has become the placebo of choice in clinical trials. The conduct of a clinical trial provided a unique opportunity to assess the treatment efficacy of CPAP among patients with OSA while evaluating the success of the sham-CPAP device as a placebo. The purpose of this article is to evaluate whether sham-CPAP was an appropriate placebo to blind participants to treatmentgroup assignment in a 4-week clinical trial.
Method Participants
We used data from 23 community-dwelling adults (active CPAP n ¼ 12, sham-CPAP n ¼ 11) in this secondary analysis.
Inclusion criteria were no prior diagnosis of OSA, an apnea þ hypopnea index (AHI) > 10, CPAP naïve, no one in household on CPAP therapy, and willingness to be randomly assigned to either group. Potential participants were excluded if they had a safety sensitive occupation, history of a sleepiness-related ''near miss'' or automobile accident, cardiovascular disturbances or prolonged hypoxia during their diagnostic sleep study, or unstable medical or psychiatric conditions. We randomly assigned participants identified with OSA to either the CPAP group or to the sham-CPAP control group. The principal investigator (PI), project manager, and participants were blinded to group assignment.
The majority of the sample was male (60%, n ¼ 14), Caucasian (52%), well educated (mean years of school ¼ 14 + 3), and subjectively sleepy at baseline (mean Epworth Sleepiness score ¼ 11 + 4 [Johns, 1991 [Johns, , 1992 ). The typical participant was middleaged (mean age ¼ 55.6 years + 10.6), overweight or obese (mean body mass index (BMI) ¼ 35.5 kg/m 2 + 6.2), and had moderate-to-severe sleep apnea (mean AHI ¼ 39 + 26).
CPAP and Sham-CPAP Placebo Devices
Philips Respironics (Murrysville, PA) provided both the CPAP and the sham-CPAP devices to the study without charge. The sham circuit used to create a CPAP placebo device was similar in design to the ones used in previous studies of CPAP efficacy (Kushida et al., 2006; Rodway et al., 2010) . As Rodway described and illustrated, a hidden leak and a restrictor in the connector between the mask and CPAP tubing allowed air to escape and prevented the rebreathing of carbon dioxide. We set the pressure to 0.5-1 cm H 2 O at the mask to generate sufficient airflow and create a blower noise to simulate treatment. The sham-CPAP device does not deliver therapeutic pressure or produce clinically meaningful alterations in pretreatment AHI, nadir of oxygen desaturation, arousal index, or sleep efficiency (Kushida et al., 2006) .
Informed Consent
We obtained approval for this study from the institutional review board at the University of Pittsburgh and informed consent from all participants prior to proceeding with any study activity to determine eligibility. During the informed consent process, we informed potential participants that CPAP is the treatment for OSA used in clinical practice and described the treatment as a mask that is fitted over the nose and connected to a machine that delivers air at positive pressure to act as a pneumatic ''splint'' to prevent breath holding or decreased breathing while sleeping. We described sham-CPAP as appearing very similar but not treating their OSA. We advised participants that their being assigned CPAP or sham-CPAP was random, ''like flipping a coin,'' where a computer placed them into one or the other treatment group. We advised all subjects that they might continue to be sleepy and, if so, should not drive or operate dangerous equipment, even if they were in the active CPAP group.
Diagnostic Sleep Study
Potential participants underwent an overnight in-laboratory diagnostic polysomnogram (PSG) sleep study at the Neuroscience Clinical and Translational Research Center (N-CTRC) at the University of Pittsburgh Medical Center.
To determine the presence and severity of OSA, the PSG detected episodes of collapse of the upper airway that result in a cessation of airflow for >10 s (apnea) or reduction in airflow (hypopnea) of at least 30% associated with a drop of at least 4% in oxygen saturation. The following signals were recorded: electroencephalogram, electrooculograms (right and left outer canthi), electromyograms (bipolar submental and bilateral tibialis anterior), thoracic and abdominal expansion, nasal and oral airflow, pulse oximetry, and electrocardiogram. The sleep study was staged according to the recommendations of the American Academy of Sleep Medicine (AASM; American Academy of Sleep Medicine Task Force, 1999). The trained polysomnography technicians at the N-CTRC completed the initial scoring. Quality assurance is maintained within the center with routine interrater reliability evaluations. An AASM board certified physician then evaluated the studies.
Titration of CPAP or Sham-CPAP
Participants who met all the inclusion and exclusion criteria were randomly assigned to either the active CPAP or sham-CPAP groups. We titrated the participants to either active or sham-CPAP during overnight, in-laboratory sleep studies, identical for the two groups except for the titration of positive pressure to active-CPAP participants. We educated all participants about the diagnosis of OSA and how to use their device at home. We then loaned them either a CPAP or a sham-CPAP machine to take home for 4 weeks and encouraged them to use their device for their entire sleep period every night. We monitored adherence to wearing the CPAP/sham-CPAP device with a SmartCard 1 that measured the time during which the device was worn. Participants mailed the SmarCard 1 to the project manager once a week for adherence monitoring. We called participants the morning after their first night of CPAP/sham-CPAP use at home.
Debriefing
Prior to revealing group assignment, we asked all participants to ''guess'' to which group they had been assigned. The investigator and project manager talked with participants one-on-one for the debriefing. They provided all participants with copies of their sleep studies and encouraged them to communicate with their health care providers about continuing on CPAP therapy.
Statistical Analysis
We present summary statistics as mean (SD) plus range for continuous variables (age, BMI, and AHI) and as frequencies for the categorical data (sex and race). We used independent-sample t-tests to examine differences in demographic variables and adherence between active and sham-CPAP participants. We conducted data analysis using IBM SPSS 19 software. We used an ''intent-to-treat'' (ITT) approach when exploring treatment efficacy, including all participants in the data analysis based on their group assignment.
Results
The sham-CPAP and the active CPAP groups were similar in age, sex distribution, BMI, number of years of education, and subjective sleepiness, as shown in Table 1 . At baseline, participants in the active CPAP group had significantly higher mean AHI and oxygen desaturation indexes than those in the sham-CPAP group (p < .05), as shown in Table 2 . As expected, active CPAP demonstrated treatment efficacy with a significant reduction in mean AHI, while sham-CPAP did not (p ¼ .001). Participants on sham-CPAP had no significant differences in sleep latency, total sleep time, AHI, oxygen desaturation index and nadir, or arousal index between their diagnostic sleep study and their sham-CPAP titration sleep study.
We observed no significant differences in age, sex, number of years of education, or AHI between those participants who were correct and those who were incorrect in their appraisal of treatment-group assignment. When questioned, 10 of the 23 participants (44%) were incorrect in their guess of group assignment; of these, 2 participants stated that their guesses were ''random.'' There was a 95% retention rate of participants in the study. The one participant who chose to quit the study ''guessed'' he was on active CPAP but stated that ''it wasn't helping any''; this participant was actually on sham-CPAP. He stated that he understood the concept of being randomly assigned to either active or sham-CPAP.
Participants on both active and sham-CPAP were incorrect in their appraisals of group assignment (active CPAP þ correct guess n ¼ 7 [30%]; sham-CPAP þ correct guess n ¼ 6 [26%]; active CPAP þ incorrect guess n ¼ 5 [22%]; and sham-CPAP þ incorrect guess n ¼ 5 [22%]). There were no statistically significant differences between the active CPAP and sham-CPAP groups' average minutes per day of device usage or percentage of days when they used their devices 4 or more hr a night (CPAP 269 + 140 min/day, 65% of nights vs. sham-CPAP 170 + 118 min/day, 41% of nights. In Table 3 , we present the descriptive statistics of the minutes of adherence to either CPAP or sham-CPAP and the percentage of days with 4 or more hr of device usage according to treatment group assignment and by the participants' perception of whether they were on active treatment.
Discussion
In this secondary analysis, we examined whether the sham-CPAP device serves as an adequate placebo treatment in clinical trials of CPAP efficacy. Results suggest that participants were blind to group membership whether they had been randomized to the active or sham-CPAP group. Although 56% of the subjects were correct in their ''guess'' of the correct assignment, this result is only slightly higher than what one could expect from chance. The use of sham-CPAP more closely approximates the experience of actual CPAP than early methods that used an oral placebo tablet (Barnes et al., 2002; Engleman et al., 1999) . We also found that sham-CPAP has a minimal effect on OSA severity, a finding that agrees with Rodway and colleagues' (2010) previous report. Our results strengthen the evidence that, when appropriate safeguards are incorporated into the study design, participants can remain blind to group assignment and that sham-CPAP can be an effective placebo control device in studies evaluating the effects of CPAP. Investigators utilizing sham-CPAP need to be attentive to monitoring adherence and encourage all subjects to be fully adherent to wearing their device. Weaver et al. (1997) described the use of CPAP with a bimodal distribution of ''adherent'' patients who average 6-hr use nightly and ''nonadherent'' patients who routinely ''skip'' using their CPAP or average less than 4 hr a night. Data from several studies suggest that patients decide during the first week of CPAP treatment whether or not to be adherent (Aloia, Arnedt, Stanchina, & Millman, 2007; Weaver et al., 1997) . In our study, the perception of not being in the active treatment group was associated with lower adherence both in the total device usage and in the percentage of days worn. An implication for future study is exploration of the association between perceived benefit of treatment and adherence to treatment.
In the current study, we were careful in attending to potential ethical issues. According to Brown et al. (2011) , clinical trials in OSA have specific ethical issues that must be addressed. These include clinical equipoise, uncertainty about the benefit of the treatment, and protection of subjects from potential harm. The informed consent must provide full disclosure by emphasizing that the study is for research not clinical care, and participants must understand that they have the right to withdraw consent at any time. In addition, studies utilizing sham-CPAP require close monitoring for potential problems and involvement by the safety officer and data safety monitoring board.
A limitation of this study is that it presents data from a pilot or feasibility study that had a small sample size, which increases the risk for a Type II error. This limitation might affect the validity of measurement of outcomes associated with the primary variable, assignment to either active or sham-CPAP. In addition, exclusion of subjects that may have been inappropriate for sham-CPAP may have limited the generalizability of the results of the study to such individuals. In summary, CPAP-naïve participants with OSA can remain blind to group assignment despite being assigned to a sham-CPAP device. The results from this study strengthen the evidence that sham-CPAP can be an appropriate placebo control device in studies evaluating the effects of treatment of OSA with CPAP. Further study is needed to determine whether a well-designed observational study can yield results that are comparable to randomized clinical trials in clarifying treatment effects of CPAP in patients with OSA.
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Group and guess
Average device usage all days (min; mean + SD)
Percentage of days with usage > 4 hr (%)
Assigned to active CPAP (n ¼ 12)
Guessed they were in active CPAP (n ¼ 7) 275 + 134 68 Guessed they were in sham-CPAP (n ¼ 5) 260 + 163 60 Assigned to sham-CPAP (n ¼ 11)
Guessed they were in sham-CPAP (n ¼ 6) 165 + 122 41 Guessed they were in active-CPAP (n ¼ 5) 176 + 127 41
Note. CPAP ¼ continuous positive airway pressure.
